Kim SY - Search Results

1

A Paradoxical Effect of Interleukin-32 Isoforms on Cancer.

Shim S, Lee S, Hisham Y, Kim S, Nguyen TT, Taitt AS, Hwang J, Jhun H, Park HY, Lee Y, Yeom SC, Kim SY, Kim YG, Kim S. Shim S, et al. Among authors: kim s, kim sy, kim yg. Front Immunol. 2022 Feb 25;13:837590. doi: 10.3389/fimmu.2022.837590. eCollection 2022. Front Immunol. 2022. PMID: 35281008 Free PMC article. Review.

2

IL-32γ attenuates airway fibrosis by modulating the integrin-FAK signaling pathway in fibroblasts.

Hong GH, Park SY, Kwon HS, Bang BR, Lee J, Kim SY, Pack CG, Kim S, Moon KA, Kim TB, Moon HB, Cho YS. Hong GH, et al. Among authors: kim sy, kim s, kim tb. Respir Res. 2018 Sep 26;19(1):188. doi: 10.1186/s12931-018-0863-3. Respir Res. 2018. PMID: 30257681 Free PMC article.

3

Comparison of the Seven Interleukin-32 Isoforms' Biological Activities: IL-32θ Possesses the Most Dominant Biological Activity.

Shim S, Lee S, Hisham Y, Kim S, Nguyen TT, Taitt AS, Hwang J, Jhun H, Park HY, Lee Y, Yeom SC, Kim SY, Kim YG, Kim S. Shim S, et al. Among authors: kim s, kim sy, kim yg. Front Immunol. 2022 Feb 25;13:837588. doi: 10.3389/fimmu.2022.837588. eCollection 2022. Front Immunol. 2022. PMID: 35281066 Free PMC article.

4

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer.

Ku BM, Kim Y, Lee KY, Kim SY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Ku BM, et al. Among authors: kim sy, kim y. Eur J Immunol. 2021 Apr;51(4):956-964. doi: 10.1002/eji.202048966. Epub 2021 Feb 22. Eur J Immunol. 2021. PMID: 33506525 Free PMC article.

5

Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.

Kim JH, Kim GH, Ryu YM, Kim SY, Kim HD, Yoon SK, Cho YM, Lee JL. Kim JH, et al. Among authors: kim gh, kim sy, kim hd. Front Oncol. 2022 Sep 27;12:969569. doi: 10.3389/fonc.2022.969569. eCollection 2022. Front Oncol. 2022. PMID: 36237314 Free PMC article.

6

Comprehensive evaluation of the tumor immune microenvironment and its dynamic changes in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy: From the phase II ADORE study.

Cho H, Kim JE, Hong YS, Kim SY, Kim J, Ryu YM, Kim SY, Kim TW. Cho H, et al. Among authors: kim tw, kim sy, kim je, kim j. Oncoimmunology. 2022 Nov 23;11(1):2148374. doi: 10.1080/2162402X.2022.2148374. eCollection 2022. Oncoimmunology. 2022. PMID: 36451674 Free PMC article. Clinical Trial.

7

Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer.

Kim HD, Kim JH, Ryu YM, Kim D, Lee S, Shin J, Hong SM, Kim KH, Jung DH, Song GW, Hwang DW, Lee JH, Song KB, Ryoo BY, Jeong JH, Kim KP, Kim SY, Yoo C. Kim HD, et al. Among authors: kim d, kim kp, kim sy, kim kh, kim jh. Cancer Res Treat. 2021 Jan;53(1):162-171. doi: 10.4143/crt.2020.704. Epub 2020 Aug 31. Cancer Res Treat. 2021. PMID: 32878426 Free PMC article.

8

siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model.

Jung JY, Ryu HJ, Lee SH, Kim DY, Kim MJ, Lee EJ, Ryu YM, Kim SY, Kim KP, Choi EY, Ahn HJ, Chang S. Jung JY, et al. Among authors: kim dy, kim kp, kim sy, kim mj. Cells. 2021 Oct 13;10(10):2734. doi: 10.3390/cells10102734. Cells. 2021. PMID: 34685714 Free PMC article.

9

Phosphorylation of TFCP2L1 by CDK1 is required for stem cell pluripotency and bladder carcinogenesis.

Heo J, Noh BJ, Lee S, Lee HY, Kim Y, Lim J, Ju H, Yu HY, Ryu CM, Lee PC, Jeong H, Oh Y, Kim K, Kim SY, Son J, Hong B, Kim JS, Cho YM, Shin DM. Heo J, et al. Among authors: kim sy, kim js, kim y, kim k. EMBO Mol Med. 2020 Jan 9;12(1):e10880. doi: 10.15252/emmm.201910880. Epub 2019 Nov 11. EMBO Mol Med. 2020. PMID: 31709755 Free PMC article.

10

Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4.

Kim DH, Park S, Kim H, Choi YJ, Kim SY, Sung KJ, Sung YH, Choi CM, Yun M, Yi YS, Lee CW, Kim SY, Lee JC, Rho JK. Kim DH, et al. Among authors: kim h, kim sy. Cancer Lett. 2020 Apr 10;475:2-13. doi: 10.1016/j.canlet.2020.01.023. Epub 2020 Jan 28. Cancer Lett. 2020. PMID: 32004570

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12,041 results

Search Page